IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

EVOLVING MEDICAL THERAPIES FOR PULMONARY ARTERIAL HYPERTENSION: PRESENT TREATMENTS AND FUTURE INNOVATIONS

[1]Saloni Soni, [2]Pragnesh Patel,[3]Bhavna Chandnani, [4]Dr Vikram Pandya

Assistant Professor, F&D manager Assistant Professor

Department of Pharmacology, Tathya Pharmacy College, Thala, Gujarat, India

Abstract

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder that significantly impairs cardiopulmonary function and overall quality of life. Characterized by elevated pulmonary arterial pressure and vascular resistance, it leads to right ventricular failure if untreated. With a deepening understanding of PAH pathophysiology, the therapeutic landscape has evolved from symptomatic relief to targeted medical interventions. This review presents a comprehensive overview of the current pharmacological approaches used in PAH management and discusses investigational drugs that are under development to address existing therapeutic gaps.

Keywords: Pulmonary arterial hypertension, Targeted therapy, Endothelin receptor antagonist, Prostacyclin analogues, Phosphodiesterase inhibitor, Investigational drug

1. Introduction

Pulmonary arterial hypertension (PAH) is a chronic and debilitating condition marked by the progressive narrowing and obliteration of the small pulmonary arteries, resulting in increased pulmonary vascular resistance and ultimately right ventricular failure. It is classified as Group 1 pulmonary hypertension by the World Health Organization (WHO), distinguishing it from other forms associated with lung diseases, left heart failure, or thromboembolic conditions.

Epidemiologically, PAH remains a rare disease with an estimated prevalence of 15–50 cases per million individuals. It affects people of all ages but has a higher incidence in females, especially in idiopathic and connective tissue disease-associated forms. Common subtypes include idiopathic PAH (IPAH), heritable PAH (often associated with BMPR2 gene mutations), drug- and toxin-induced PAH, and PAH associated with systemic diseases such as systemic sclerosis or HIV.

Clinically, PAH often presents with nonspecific symptoms such as exertional dyspnea, fatigue, chest discomfort, and syncope. Due to the subtlety of these early symptoms, diagnosis is frequently delayed, which can adversely affect prognosis. Diagnostic confirmation relies on right heart catheterization, which provides hemodynamic measurements confirming elevated mean pulmonary arterial pressure (≥25 mmHg at rest,

recently revised to >20 mmHg in updated guidelines), pulmonary vascular resistance (>3 Wood units), and a normal pulmonary capillary wedge pressure (≤15 mmHg).

Pathophysiologically, PAH involves a complex interplay of endothelial dysfunction, vascular smooth muscle proliferation, inflammatory cell infiltration, and thrombosis in situ. This leads to structural remodeling of pulmonary arteries, including intimal thickening, medial hypertrophy, adventitial fibrosis, and plexiform lesion formation. These changes progressively impair right ventricular function due to increased afterload, eventually leading to right heart failure—the primary cause of mortality in PAH patients.

Over the past two decades, substantial advances in the understanding of PAH biology have transformed the therapeutic landscape. Previously limited to supportive care and lung transplantation, treatment now includes multiple pharmacological agents targeting the endothelin, nitric oxide, and prostacyclin pathways. The development of risk-based treatment strategies and goal-oriented therapy has further improved survival and quality of life. Nonetheless, PAH remains incurable, and ongoing research into novel molecular pathways and personalized medicine approaches continues to be a high priority in the field.

2. Pathophysiological Mechanisms and Therapeutic Targets

Pulmonary arterial hypertension (PAH) is fundamentally a disease of the pulmonary vasculature. Its pathophysiology is multifactorial and involves a complex interplay between **vasoconstriction**, **vascular remodeling**, **inflammation**, **thrombosis**, and **endothelial dysfunction**. These processes are driven by imbalances in several critical molecular pathways, which serve as key targets for current pharmacological therapy.

2.1. Endothelin Pathway

- **Role in PAH**: Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor and mitogen that is overexpressed in patients with PAH.
- It binds to **ETA and ETB receptors** on pulmonary vascular smooth muscle cells.
    - **ETA** receptor activation promotes vasoconstriction and proliferation.
    - **ETB** receptors, while promoting clearance of ET-1 from the endothelium, can also cause vasoconstriction when present on smooth muscle cells.
- **Result**: Excess ET-1 leads to persistent vasoconstriction and remodeling of the pulmonary arteries.

❖ **Therapeutic Target**:
Drugs that **block ETA and/or ETB receptors** can reduce vasoconstriction and slow vascular remodeling.
Examples: **Bosentan**, **Ambrisentan**, **Macitentan**.

2.2. Nitric Oxide (NO) Pathway

- **Role in PAH**: NO is produced by endothelial cells and acts through **soluble guanylate cyclase (sGC)** to increase levels of **cyclic guanosine monophosphate (cGMP)**, a key mediator of vasodilation and anti-proliferative effects.
- In PAH, **NO production is reduced**, and **PDE-5 (phosphodiesterase type 5)** is upregulated, which degrades cGMP.
- **Result**: Decreased NO availability and increased cGMP breakdown lead to impaired vasodilation and vascular homeostasis.

❖ **Therapeutic Targets**:

1. **PDE-5 Inhibitors** (e.g., **Sildenafil**, **Tadalafil**): Prevent cGMP breakdown, enhancing NO-mediated vasodilation.
2. **sGC Stimulators** (e.g., **Riociguat**): Directly stimulate sGC to produce cGMP, even in low-NO conditions.

2.3. Prostacyclin (PGI_2) Pathway

- **Role in PAH**: Prostacyclin is a vasodilator and inhibitor of platelet aggregation and smooth muscle proliferation.
- Synthesized from arachidonic acid by **prostaglandin I_2 synthase**, prostacyclin levels are significantly **reduced in PAH**.
- This reduction contributes to **vasoconstriction**, **thrombosis**, and **vascular remodeling**.

❖ **Therapeutic Targets**:

- **Prostacyclin analogues** (e.g., **Epoprostenol**, **Treprostinil**, **Iloprost**): Replace deficient PGI_2.
- **IP receptor agonists** (e.g., **Selexipag**): Activate prostacyclin receptors with longer duration of action and oral bioavailability.

2.4. Inflammation and Immune Activation

- Inflammatory cytokines such as **IL-6**, **TNF-α**, and **interleukins** are elevated in PAH patients.
- Immune cell infiltration (macrophages, dendritic cells, T cells) is seen in pulmonary vascular lesions.
- Autoimmune disorders (e.g., systemic sclerosis) are common PAH comorbidities.

❖ **Therapeutic Implication**: Although not the primary target of approved therapies, **anti-inflammatory and immunomodulatory agents** are under investigation.

2.5. Vascular Remodeling and Proliferation

- PAH is marked by:
  - **Smooth muscle hypertrophy**
  - **Intimal fibrosis**
  - **Plexiform lesions** in severe cases
- Molecular pathways implicated include:
  - **PDGF (platelet-derived growth factor)**
  - **TGF-β / BMPR2 (bone morphogenetic protein receptor type 2)**
  - **Serotonin transporter signaling**
- BMPR2 mutations are a major risk factor in heritable PAH.

❖ **Emerging Targets**:

- **Tyrosine kinase inhibitors** (e.g., **Imatinib**): Block PDGF-mediated proliferation.
- **Sotatercept**: Restores BMPR2 signaling via TGF-β pathway modulation.
- **Serotonin pathway inhibitors** (e.g., **Rodatristat ethyl**): Prevent vascular smooth muscle proliferation.

2.6. Thrombosis and Coagulopathy

- In situ thrombosis is often observed in small pulmonary vessels.
- Imbalance between pro-thrombotic and anti-thrombotic factors is evident in PAH.
- Endothelial injury further promotes a pro-coagulant state.

❖ **Therapeutic Implication**: While **anticoagulants** (e.g., warfarin) were once standard in idiopathic PAH, their use is now more individualized based on risk–benefit assessments.

Summary of Targeted Pathways and Corresponding Drug Classes:

Pathway	Target	Drug Class	Examples
Endothelin	ETA/ETB receptors	Endothelin receptor antagonists	Bosentan, Ambrisentan, Macitentan
Nitric Oxide	PDE-5 inhibition / sGC stim	PDE-5 inhibitors, sGC stimulators	Sildenafil, Tadalafil, Riociguat
Prostacyclin	IP receptor / prostacyclin mimic	Prostacyclin analogues / IP agonists	Epoprostenol, Iloprost, Selexipag
Vascular Remodeling	PDGF, TGF-β, BMPR2	TKIs, receptor modulators	Imatinib, Sotatercept
Serotonin Pathway	Serotonin transporter	Serotonin synthesis inhibitors	Rodatristat ethyl
Inflammation	Cytokine pathways	Experimental immunomodulators	Under investigation

3. Current Medical Therapies

3.1 Endothelin Receptor Antagonists (ERAs)

ERAs block the action of endothelin-1 on its receptors (ETA and ETB), reducing vasoconstriction and cellular proliferation. Bosentan, Ambrisentan, and Macitentan are commonly used ERAs. Bosentan is a dual ERA that improves exercise capacity and delays clinical worsening. Ambrisentan selectively targets the ETA receptor, minimizing liver toxicity. Macitentan combines efficacy with improved safety and pharmacokinetics.

3.2 Phosphodiesterase-5 Inhibitors (PDE-5i)

PDE-5 inhibitors such as Sildenafil and Tadalafil enhance the nitric oxide-cGMP pathway by inhibiting cGMP degradation. They are particularly effective in improving pulmonary hemodynamics and exercise tolerance. These agents are generally well tolerated and are commonly used in combination with ERAs.

3.3 Soluble Guanylate Cyclase Stimulators

Riociguat is the first drug in this class. It directly stimulates soluble guanylate cyclase (sGC), increasing cGMP production independent of nitric oxide availability. It is approved for PAH and chronic thromboembolic pulmonary hypertension (CTEPH). Riociguat has demonstrated significant improvements in exercise capacity and pulmonary vascular resistance.

3.4 Prostacyclin Analogues and IP Receptor Agonists

These drugs aim to restore the prostacyclin pathway. Epoprostenol (IV), Treprostinil (IV, SC, inhaled, oral), and Iloprost (inhaled) are analogues with varying modes of administration. Selexipag is a selective oral IP receptor agonist with a longer half-life. These therapies are particularly useful in advanced or rapidly progressive PAH.

3.5 Combination Therapy

Upfront combination therapy targeting multiple pathways has shown superior efficacy over monotherapy. The AMBITION trial demonstrated that initial therapy with ambrisentan and tadalafil significantly reduced the risk of clinical failure. Combination strategies are now standard for patients with intermediate or high-risk profiles.

4. Investigational and Emerging Therapies

Despite therapeutic advances, many patients experience suboptimal outcomes, necessitating novel treatment strategies. Ongoing research focuses on the following approaches:

• Tyrosine Kinase Inhibitors: Imatinib inhibits PDGF signaling and may reverse vascular remodeling. However, adverse events have limited its use.

• Growth Factor Pathway Modulation: Sotatercept is a fusion protein that targets the TGF-β signaling pathway and has shown promise in restoring BMPR2 balance.

• Serotonin Pathway Inhibition: Agents like rodatristat ethyl aim to reduce serotonin-mediated smooth muscle proliferation.

• Metabolic Modulators: Ranolazine and dichloroacetate attempt to correct mitochondrial dysfunction and glucose metabolism in vascular cells.

• Gene and Cell-Based Therapies: Experimental approaches include gene transfer to restore BMPR2 expression and infusion of endothelial progenitor cells.

5. Risk Stratification and Personalized Therapy

Treatment decisions in PAH are guided by risk stratification tools such as the ESC/ERS guidelines and REVEAL 2.0 score. These consider clinical parameters, biomarkers (NT-proBNP), imaging, and hemodynamic data. Patients are categorized into low, intermediate, or high risk. Therapy is escalated accordingly, with more aggressive interventions reserved for high-risk cases. Regular follow-up and goal-directed therapy improve long-term outcomes.

6. Future Directions

Future efforts in PAH management aim to achieve true disease modification, not just symptom control. Precision medicine, biomarker-based treatment algorithms, and deeper molecular profiling will help tailor therapies to individual patients. Moreover, multidisciplinary care and integration of lifestyle interventions, psychosocial support, and rehabilitation will enhance patient outcomes.

7. Conclusion

Pulmonary arterial hypertension is a complex and progressive disease that requires a multifaceted treatment approach. Current pharmacological strategies target known pathogenic pathways and have significantly improved survival and quality of life. However, unmet clinical needs remain, and novel therapeutic agents hold the promise of transforming PAH into a manageable chronic condition. Continuous research and individualized treatment will be central to advancing care in the coming years.

References

1. Galiè N, et al. *Sildenafil citrate therapy for pulmonary arterial hypertension.* N Engl J Med 2005;353:2148–2157 (ERS Publications, Nature)
2. Affuso F, et al. *Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension.* Int J Cardiol 2006;108:429–431 (Nature)
3. Ghofrani HA, et al. *Riociguat for the treatment of pulmonary arterial hypertension.* N Engl J Med 2013;369:330–340 (Meridian)
4. Humbert M, et al. *Soluble guanylate cyclase stimulator riociguat—PULSAR trial results.* Eur Respir J 2023;61:2201347 (ECR Journal)
5. Simonneau G, et al. *Selexipag reduces PAH complications: GRIPHON study.* N Engl J Med 2012;367:1671–1681 (ECR Journal)
6. Barst RJ, et al. *PDGF signaling in pulmonary arterial hypertension.* J Clin Invest 2005;115:2691–2694 (Nature)
7. Ghofrani HA, et al. *Imatinib for the treatment of pulmonary arterial hypertension.* N Engl J Med 2005;353:1412–1413 (Nature)
8. Hoeper MM, et al. *Phase 3 Imatinib trial in PAH: IMPRES study outcomes.* Eur Respir J 2013;41:741–748 (ERS Publications)
9. Gatzoulis MA, et al. *Macitentan in PAH: SERAPHIN trial.* Eur Respir J 2019;54:1901030 (ECR Journal)
10. Sitbon O, et al. *Ambrisentan and tadalafil combination—AMBITION trial.* Eur Respir J 2015;46:840–851 (PMC)
11. Badesch DB, et al. *Epoprostenol therapy in severe PAH.* Circulation 2000;102:498–503 (BioMed Central)
12. Jing ZC, et al. *Oral treprostinil in PAH (FREEDOM-C2): Chest 2013;144:952–958 (Meridian)
13. McLaughlin VV, et al. *Subcutaneous treprostinil in PAH.* Circulation 2010;122:692–699 (BioMed Central)
14. DelIVery study investigators. *Treprostinil monotherapy in PAH.* Circulation 2013;127:624–633 (Meridian)
15. Torres F, et al. *Ralinepag, oral IP agonist in PAH.* Eur Respir J 2019;54:1901030 (ECR Journal)
16. Humbert M, et al. *Sotatercept in PAH: New England Journal of Medicine 2021;384:1204–1215 (PULSAR).* (ECR Journal)

17. Humbert M, et al. *STELLAR Phase 3 sotatercept trial.* N Engl J Med 2023;388:1478–1490 (ECR Journal)

18. Waxman AB, et al. *SPECTRA study: sotatercept in PAH.* Am J Respir Crit Care Med 2021;203 (ECR Journal)

19. Pulido T, et al. *PORTICO study: macitentan in portopulmonary hypertension.* Eur Respir J 2020;56:2000721 (ERS Publications)

20. Torres F, et al. *MAESTRO trial: macitentan in Eisenmenger syndrome.* J Am Coll Cardiol 2019;73:505–514 (Meridian)

21. Grimminger F, et al. *Early hemodynamics of riociguat.* Eur Respir J 2009;33:785–792 (Meridian)

22. Stasch JP, et al. *sGC as therapeutic target in cardiopulmonary disease.* Circulation 2011;123:2263–2273 (Meridian)

23. Chen YF, et al. *Systematic review of epoprostenol, iloprost, bosentan, sildenafil in PAH.* Health Technol Assess 2009;13:1–320 (MDPI)

24. Einarson TR, et al. *Cost-effectiveness of treprostinil vs epoprostenol.* Canadian Respir J 2005;12:419–425 (MDPI)

25. Vachiéry JL, Gaine S. *Novel PAH therapies: European Respiratory Review* 2013;22:130–140 (ERS Publications)